Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 15.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 76,017 shares of the biotechnology company’s stock after acquiring an additional 10,264 shares during the period. Teacher Retirement System of Texas’ holdings in Exelixis were worth $2,531,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Tri Ri Asset Management Corp acquired a new stake in shares of Exelixis in the third quarter valued at approximately $4,396,000. Blue Trust Inc. grew its holdings in Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 8,208 shares during the last quarter. Range Financial Group LLC acquired a new stake in Exelixis during the 4th quarter valued at $994,000. FMR LLC increased its position in Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after buying an additional 140,568 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after acquiring an additional 704,786 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by company insiders.

Exelixis Trading Down 1.9 %

Shares of Exelixis stock opened at $37.01 on Thursday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The stock has a market cap of $10.36 billion, a price-to-earnings ratio of 20.91, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company has a fifty day moving average price of $35.69 and a 200 day moving average price of $33.12.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on EXEL. Stephens reiterated an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Exelixis in a report on Thursday, February 13th. Bank of America downgraded shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. Wells Fargo & Company cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price for the company. in a research note on Monday, February 24th. Finally, Barclays increased their price target on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.